Jayex Technology Ltd (ASX: JTL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Jayex Technology Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$281278.539
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
281.28 million
Earnings per share
-0.015
Dividend per share
N/A
Year To Date Return
-88.89%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Jayex Technology Ltd (ASX: JTL)
Latest News
No posts found.
JTL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Jayex Technology Ltd
Jayex Technology Ltd is a company operating in the healthcare industry. The company is engaged in developing and providing service technologies for the healthcare industry and also in developing integrated dispensing automation systems forthe pharmaceutical and healthcare sectors. Jayex Technology provides healthcare systems that help manage appointments and communicate patient information effectively. The company's main products and services consist of healthcare industry service technologies. Jayex Technology operates in two segments, namely Australia and the United Kingdom, with the majority of its revenue generated in the United Kingdom.
JTL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 25 Jul 2024 | $0.00 | $0.00 | 0.00% | 1,604,482 | $0.00 | $0.00 | $0.00 |
| 24 Jul 2024 | $0.00 | $0.00 | 0.00% | 2,210,000 | $0.00 | $0.00 | $0.00 |
| 23 Jul 2024 | $0.00 | $0.00 | 0.00% | 2,045,668 | $0.00 | $0.00 | $0.00 |
| 22 Jul 2024 | $0.00 | $0.00 | 0.00% | 65,206 | $0.00 | $0.00 | $0.00 |
| 18 Jul 2024 | $0.00 | $0.00 | 0.00% | 440 | $0.00 | $0.00 | $0.00 |
| 17 Jul 2024 | $0.00 | $0.00 | 0.00% | 1,337,965 | $0.00 | $0.00 | $0.00 |
| 05 Jul 2024 | $0.00 | $0.00 | 0.00% | 750,500 | $0.00 | $0.00 | $0.00 |
| 04 Jul 2024 | $0.00 | $0.00 | 0.00% | 517,754 | $0.00 | $0.00 | $0.00 |
| 02 Jul 2024 | $0.00 | $0.00 | 0.00% | 2,319,567 | $0.00 | $0.00 | $0.00 |
| 28 Jun 2024 | $0.00 | $0.00 | 0.00% | 500,000 | $0.00 | $0.00 | $0.00 |
| 26 Jun 2024 | $0.00 | $0.00 | 0.00% | 1,000,000 | $0.00 | $0.00 | $0.00 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Denis Boyd | Non-Executive ChairmanNon-Executive Director | Oct 2022 |
Mr. Boyd has been involved in the creation of new enterprises, both in the private and public sectors, for over 27 years. Mr. Boyd has been in developing and growing new projects in areas including healthcare, telecommunications and finance. He started Foundation Healthcare, growing it to over 800 healthcare professionals before it was acquired by Sonic. He was also a founding partner of Iridium Satellite bringing it out from bankruptcy to now a NASDAQ listed company.
|
| Mr William Denis Boyd | Non-Executive Director | Jun 2024 |
Mr Boyd has a history in the provision of healthcare services in Australia over the past forty years
|
| Mr Brian Renwick | Non-Executive Director | Jul 2009 |
Mr. Renwick is experienced across the pharmaceutical and healthcare sector in Australia. His involvement with sector commenced in finance roles that led into commercial analysis, marketing and sales. From this experience in the manufacturing end of the supply chain he moved into the wholesaling with various business development roles in retail and hospital pharmacy. Mr Renwick's roles broadened into commercial and business development including as general manager for a corporate pharmacy business. He has completed two Business Development roles within the CSL Limited group. With his knowledge and experience across the healthcare sector, Brian has provided consulting advice to Jayex since 2006 and is a member of the team.
|
| Ms Melanie Jaye Leydin | Company Secretary | Aug 2015 |
-
|
| Mr Robert Hadley | Chief Executive Officer | Oct 2022 |
-
|
| Robert Hadley | Chief Executive Officer |
-
|
|
| Melanie Jaye Leydin | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Lirho Pty Ltd < Boyd 4 A/C > | 103,883,880 | 36.93% |
| Vector London Ltd | 19,003,378 | 6.76% |
| Mary Kathleen Simcox | 17,500,000 | 6.22% |
| Donovan Products Pty Ltd < Family Account > | 12,035,943 | 4.28% |
| Turbine Capital Limited | 8,800,000 | 3.13% |
| Covenant Holding (Wa) Pty Ltd | 7,000,000 | 2.49% |
| Citicorp Nominees Pty Limited | 6,455,163 | 2.29% |
| Bnp Paribas Nominees Pty Ltd < Ib Au Noms Retailclient > | 5,990,327 | 2.13% |
| Mr Joel David Webb | 5,500,000 | 1.96% |
| Mrs Vanessa Faye Connor | 5,174,808 | 1.84% |
| Mr Dean Henry Cleary < The Clearway Investment A/C > | 4,140,000 | 1.47% |
| Amg Corporate Pty Ltd < The Amg Super Fund A/C > | 3,000,000 | 1.07% |
| Mr David Ariti | 2,839,777 | 1.01% |
| Mr Michael Raeburn Connor | 2,445,079 | 0.87% |
| Mr Jeremy Ruben & Mrs Vanessa Ruben < Jvr Super Fund A/C > | 2,008,067 | 0.71% |
| Mr Stephen John Hart | 2,000,000 | 0.71% |
| Mr Yuliang Fan | 2,000,000 | 0.71% |
| Ms Chunyan Niu | 2,000,000 | 0.71% |
| Super Msj Pty Ltd < Msj Super Fund A/C > | 2,000,000 | 0.71% |
| Mr Samuel Gershon Jacobs & Mrs Sarita Devi Jacobs & Miss Manekha Bridgette Jacobs | 1,977,083 | 0.70% |
